SLC35G5

Across TCGA pan-cancer cohorts, SLC35G5 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated SLC35G5 data layer compared with 23 for mass-spec protein.

The strongest signal is observed in mesothelioma (MESO), where higher SLC35G5 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated SLC35G5 expression acts as an unfavorable survival marker, although some lineages such as SCLC show a favorable association.

MESO, SCLC, and KIRC are the cancer types where SLC35G5 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
MESO	OS	Median	III,IV	0.052	0.567	<.001	36	view →
SCLC	OS	Median	II,III,IV	1.000	0.295	.030	8	view →
KIRC	OS	Median	All	0.140	0.628	.038	6	view →
TGCT	DFS	Median	II,III,IV	0.088	0.917	.010	6	view →
READ	DFS	Median	All	0.556	0.798	.037	6	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

SLC35G5–MESO (OS)

Open the MESO breakdown →